About Epiplakin
Epiplakin (EPPK1) is a protein
from Homo sapiens identified by UniProt accession
P58107, 5088 residues long.
MolForge cross-references it against 0 known binders and
69 disease associations.
Target properties
| Protein name | Epiplakin |
|---|
| UniProt accession | P58107 |
|---|
| Gene | EPPK1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 5088 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (69)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.45
- myoepithelial tumor · score 0.11
- platelet count · score 0.10
- mean platelet volume · score 0.10
- resting heart rate · score 0.09
- platelet component distribution width · score 0.09
- platelet crit · score 0.09
- lung adenocarcinoma · score 0.07
- dermatitis herpetiformis, familial · score 0.07
- cancer · score 0.06
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (5088 residues)
MSGHTLPPLP VPGTNSTEQA SVPRAMAATL GAGTPPRPQA RSIAGVYVEA SGQAQSVYAA MEQGLLPAGL GQALLEAQAA TGGLVDLARG QLLPVSKALQ QGLVGLELKE KLLAAERATT GYPDPYGGEK LALFQAIGKE VVDRALGQSW LEVQLATGGL VDPAQGVLVA PEPACHQGLL DRETWHKLSE LEPGTGDLRF LDPNTLERLT YHQLLERCVR APGSGLALLP LKITFRSMGG AVSAAELLEV GILDEQAVQG LREGRLAAVD VSARAEVRRY LEGTGSVAGV VLLPEGHKKS FFQAATEHLL PMGTALPLLE AQAATHTLVD PITGQRLWVD EAVRAGLVSP ELHEQLLVAE QAVTGHHDPF SGSQIPLFQA MKKGLVDRPL ALRLLDAQLA TGGLVCPARR LRLPLEAALR CGCLDEDTQR QLSQAGSFSD GTHGGLRYEQ LLALCVTDPE TGLAFLPLSG GPRGGEPQGP PFIKYSTRQA LSTATATVSV GKFRGRPVSL WELLFSEAIS SEQRAMLAQQ YQEGTLSVEK LAAKLSATLE QAAATARVTF SGLRDTVTPG ELLKAEIIDQ DLYERLEHGQ ATAKDVGSLA SVQRYLQGTG CIAGLLLPGS QERLSIYEAR CKGLLRPGTA LILLEAQAAT GFIIDPKANK GHSVEEALRA AVIGPDVFAK LLSAERAVTG YTDPYTGQQI SLFQAMQKGL IVREHGIRLL EAQIATGGVI DPVHSHRVPV DVAYRRGYFD QMLNLILLDP SDDTKGFFDP NTHENLTYLQ LLERCVRDPE TGLYLLPLSS TQSPLVDSAT QQAFQNLLLS VKYGRFQGQR VSAWELINSE YFSEGRRRQL LRRYRQREVT LGQVAKLLEA ETQRQADIML PALRSRVTVH QLLEAGIIDQ QLLDQVLAGT ISPEALLLMD GVRRYLCGLG AVGGVRLLPS GQRLSLYQAM RQKLLGPRVA LALLEAQAAT GTIMDPHSPE SLSVDEAVRR GVVGPELYGR LKRAEGAIAG FRDPFSGKQV SVFQAMKKGL IPWEQAARLL EAQVATGGII DPTSHHHLPM PVAIQRGYVD QEMETALSSS SETFPTPDGQ GRTSYAQLLE ECPRDETSGL HLLPLPESAP ALPTEEQVQR SLQAVPGAKD GTSLWDLLSS CHFTEEQRRG LLEDVQEGRT TVPQLLASVQ RWVQETKLLA QARVMVPGPR GEVPAVWLLD AGIITQETLE ALAQGTQSPA QVAEQPAVKA CLWGTGCVAG VLLQPSGAKA SIAQAVRDGL LPTGLGQRLL EAQVASGFLV DPLNNQRLSV EDAVKVGLVG RELSEQLGQA ERAAAGYPDP YSRASLSLWQ AMEKGLVPQN EGLPLLQVQL ATGGVVDPVH GVHLPQAAAC RLGLLDTQTS QVLTAVDKDN KFFFDPSARD QVTYQQLRER CVCDSETGLL LLPLPSDTVL EVDDHTAVAL RAMKVPVSTG RFKGCSVSLW DLLLSEYVGA DKRRELVALC RSGRAAALRQ VVSAVTTLVE AAERQPLQAT FRGLRKQVSA RDLFRAQLIS RKTLDELSQG TTTVKEVAEM DSVKRSLEGG NFIAGVLIQG TQERMSIPEA LRRHILRPGT ALVLLEAQAA TGFIIDPVEN RKLTVEEAFK AGMFGKETYV KLLSAERAVT GYTDPYTGQQ ISLFQAMQKD LIVREHGIRL LEAQIATGGI IDPVHSHRVP VDVAYRCGYF DEEMNRILAD PSDDTKGFFD PNTHENLTYL QLLERCVEDP ETGLYLLQII KKGENYVYIN EATRHVLQSR TAKMRVGRFA DQVVSFWDLL SSPYFTEDRK RELIQEYGAQ SGGLEKLLEI ITTTIEETET QNQGIKVAAI RGEVTAADLF NSRVIDQKTL HTLRVGRTGG QALSTLECVK PYLEGSGCIA GVTVPSTREV MSLHEASRKE LIPAAFATWL LEAQAATGFL LDPCTRQKLS VDEAVDVGLV NEELRERLLK AERAATGYRD PATGDTIPLF QAMQKQLIEK AEALRLLEVQ VATGGVIDPQ HHHRLPLETA YRRGCLHKDI YALISDQKHM RKRFVDPNTQ EKVSYRELQE RCRPQEDTGW LLFPVNKAAR DSEHIDDETR RALEAEQVEI TVGRFRGQKP TLWALLNSEY VTEEKKLQLV RMYRTHTRRA LQTVAQLILE LIEKQETSNK HLWFQGIRRQ ITASELLSSA IITEEMLQDL ETGRSTTQEL MEDDRVKRYL EGTSCIAGVL VPAKDQPGRQ EKMSIYQAMW KGVLRPGTAL VLLEAQAATG FVIDPVRNLR LSVEEAVAAG VVGGEIQEKL LSAERAVTGY TDPYTGQQIS LFQAMQKDLI VREHGIRLLE AQIATGGVID PVHSHRVPVD VAYRRGYFDE EMNRVLADPS DDTKGFFDPN THENLTYVQL LRRCVPDPDT GLYMLQLAGR GSAVHQLSEE LRCALRDARV TPGSGALQGQ SVSVWELLFY REVSEDRRQD LLSRYRAGTL TVEELGATLT SLLAQAQAQA RAEAEAGSPR PDPREALRAA TMEVKVGRLR GRAVPVWDVL ASGYVSRAAR EELLAEFGSG TLDLPALTRR LTAIIEEAEE APGARPQLQD AWRGPREPGP AGRGDGDSGR SQREGQGEGE TQEAAAAAAA AAARRQEQTL RDATMEVQRG QFQGRPVSVW DVLFSSYLSE ARRDELLAQH AAGALGLPDL VAVLTRVIEE TEERLSKVSF RGLRRQVSAS ELHTSGILGP ETLRDLAQGT KTLQEVTEMD SVKRYLEGTS CIAGVLVPAK DQPGRQEKMS IYQAMWKGVL RPGTALVLLE AQAATGFVID PVRNLRLSVE EAVAAGVVGG EIQEKLLSAE RAVTGYTDPY TGQQISLFQA MQKDLIVREH GIRLLEAQIA TGGVIDPVHS HRVPVDVAYQ RGYFDEEMNR VLADPSDDTK GFFDPNTHEN LTYVQLLRRC VPDPDTGLYM LQLAGRGSAV HQLSEELRCA LRDARVTPGS GALQGQSVSV WELLFYREVS EDRRQDLLSR YRAGTLTVEE LGATLTSLLA QAQAQARAEA EAGSPRPDPR EALRAATMEV KVGRLRGRAV PVWDVLASGY VSRAAREELL AEFGSGTLDL PALTRRLTAI IEEAEEAPGA RPQLQDAWRG PREPGPAGRG DGDSGRSQRE GQGEGETQEA AAAARRQEQT LRDATMEVQR GQFQGRPVSV WDVLFSSYLS EARRDELLAQ HAAGALGLPD LVAVLTRVIE ETEERLSKVS FRGLRCQVSA SELHTSGILG PETLRDLAQG TKTLQEVTEM DSVKRYLEGT SCIAGVLVPA KDQPGRQEKM SIYQAMWKGV LRPGTALVLL EAQAATGFVI DPVRNLRLSV EEAVAAGVVG GEIQEKLLSA ERAVTGYTDP YTGQQISLFQ AMQKDLIVRE HGIRLLEAQI ATGGVIDPVH SHRVPVDVAY RRGYFDEEMN RVLADPSDDT KGFFDPNTHE NLTYVQLLRR CVPDPDTGLY MLQLAGRGSA VHQLSEELRC ALRDARVTPG SGALQGQSVS VWELLFYREV SEDRRQDLLS RYRAGTLTVE ELGATLTSLL AQAQAQARAE AEAGSPRPDP REALRAATME VKVGRLRGRA VPVWDVLASG YVSRAAREEL LAEFGSGTLD LPALTRRLTA IIEEAEEAPG ARPQLQDAWR GPREPGPAGR GDGDSGRSQR EGQGEGETQE AAAATAAARR QEQTLRDATM EVQRGQFQGR PVSVWDVLFS SYLSEARRDE LLAQHAAGAL GLPDLVAVLT RVIEETEERL SKVSFRGLRR QVSASELHTS GILGPETLRD LAQGTKTLQE VTEMDSVKRY LEGTSCIAGV LVPAKDQPGR QEKMSIYQAM WKGVLRPGTA LVLLEAQAAT GFVIDPVRNL RLSVEEAVAA GVVGGEIQEK LLSAERAVTG YTDPYTGQQI SLFQAMQKDL IVREHGIRLL EAQIATGGVI DPVHSHRVPV DVAYRRGYFD EEMNRVLADP SDDTKGFFDP NTHENLTYVQ LLRRCVPDPD TGLYMLQLAG RGSAVHQLSE ELRCALRDAR VTPGSGALQG QSVSVWELLF YREVSEDRRQ DLLSRYRAGT LTVEELGATL TSLLAQAQAQ ARAEAEAGSP RPDPREALRA ATMEVKVGRL RGRAVPVWDV LASGYVSRAA REELLAEFGS GTLDLPALTR RLTAIIEEAE EAPGARPQLQ DAWRGPREPG PAGRGDGDSG RSQREGQGEG ETQEAAAATA AARRQEQTLR DATMEVQRGQ FQGRPVSVWD VLFSSYLSEA RRDELLAQHA AGALGLPDLV AVLTRVIEET EERLSKVSFR GLRRQVSASE LHTSGILGPE TLRDLAQGTK TLQEVTEMDS VKRYLEGTSC IAGVLVPAKD QPGHQEKMSI YQAMWKGVLR PGTALVLLEA QAATGFVIDP VRNLRLSVEE AVAAGVVGGE IQEKLLSAER AVTGYTDPYT GQQISLFQAM QKDLIVREHG IRLLEAQIAT GGVIDPVHSH RVPVDVAYRR GYFDEEMNRV LAHPSDDTKG FFDPNTHENL TYVQLLRRCV PDPDTGLYML QLAGRGSAVH QLSEELRCAL RDARVMPGSG ALQGQSVSVW ELLFYREVSE DRRQDLLSRY RAGTLTVEEL GATLTSLLAQ AQAQARAEAE AEAGSPRPDP REALRAATME VKVGRLRGRA VPVWDVLASG YVSGAAREEL LAEFGSGTLD LPALTRRLTA IIEEAEEAPG ARPQLQDAWR GPREPGPAGR GDGDSGRSQR EGQGEGETQE AAAAARRQEQ TLRDATMEVQ RGQFQGRPVS VWDVLFSSYL SEAHRDELLA QHAAGALGLP DLVAVLTRVI EETEERLSKV SFRGLRRQVS ASELHTSGIL GPETLRDLAQ GTKTLQEVTE MDSVKRYLEG TSCIAGVLVP AKDQPGRQEK MSIYQAMWKG VLRPGTALVL LEAQAATGFV IDPVRNLRLS VEEAVAAGVV GGEIQEKLLS AERAVTGYTD PYTGQQISLF QAMQKDLIVR EHGIRLLEAQ IATGGVIDPV HSHRVPVDVA YRRGYFDEEM NRVLADPSDD TKGFFDPNTH ENLTYLQLLQ RATLDPETGL LFLSLSLQ
Explore Epiplakin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets